CBS 2019
CBSMD教育中心
中 文

Mitral/Tricuspid Valvular Disease

Abstract

Recommended Article

1-Year Outcomes After Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation: Results From the TriValve Registry The Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure Index: Association With All-Cause Mortality in Patients With Moderate or Severe Tricuspid Regurgitation Initial experience with percutaneous mitral valve repair in patients with cardiac amyloidosis Transcatheter Interventions for Mitral Regurgitation: Multimodality Imaging for Patient Selection and Procedural Guidance Prognostic importance of the transmitral pressure gradient in mitral annular calcification with associated mitral valve dysfunction Prevalence and clinical implications of valvular calcification on coronary computed tomography angiography Current Status and Future Prospects of Transcatheter Mitral Valve Replacement: JACC State-of-the-Art Review Thrombotic Risk and Antithrombotic Strategies After Transcatheter Mitral Valve Replacement

Original Research25 May 2021

JOURNAL:Eurointervention. Article Link

Incidence and Standardized Definitions of Mitral Valve Leaflet Adverse Events After Transcatheter Mitral Valve Repair: the EXPAND Study

FM Asch, SH Little, GB Mackensen et al. Keywords: mitral valve leaflet adverse events; LAE; definition; MitraClip;

ABSTRACT

BACKGROUND - An independent panel of experts reviewed all investigator-reported cases of mitral valve leaflet adverse events (LAE) after MitraClipTM NTR/XTR in the EXPAND Study.


AIMS - We aimed to report the findings of the expert panel and standardize definitions for LAE.


METHODS - Standard definitions for different types of LAE were formulated and events adjudicated after detailed review by the expert panel.


RESULTS - Enrolling centers reported LAE in 35 cases, 11 leaflet injuries (9 tear, 2 perforation) and 24 single leaflet device attachment (SLDA). The panel confirmed LAE in 20 cases (2.0% incidence), 18 patients had SLDA and 4 had leaflet injury (2 cases had both SLDA and injury). Leaflet injury occurred during device implant and resulted in surgical valve replacement or death. SLDA-alone events were identified during implant (n=2), pre-discharge (7) or at 30 days of follow-up (7) and were resolved (£ 2+ residual MR) with additional clips in 75% of cases.


CONCLUSIONS - Mitral valve repair with MitraClipTM NTR/XTR is safe. The rate of LAE is lower than previously reported using older generation devices. The proposed definitions and findings will help differentiate leaflet injury from inadequate leaflet insertion and SLDA, and provide guidance to consistently diagnose LAE post MitraClipTM.